FL 501
Alternative Names: FL-501Latest Information Update: 23 May 2025
At a glance
- Originator Adimab; Flame Biosciences
- Developer Leap Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Growth differentiation factor 15 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cachexia
Most Recent Events
- 13 May 2025 Pharmacodynamics and adverse events data from preclinical trials in Cachexia released by Leap Therapeutics
- 25 Apr 2025 Pharmacodynamics data from preclinical studies in Cachexia presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Pharmacokinetics and pharmacodynamics data from preclinical trials in Cachexia released by Leap Therapeutics